Waehrens J, Gerlach J
J Affect Disord. 1981 Jun;3(2):193-202. doi: 10.1016/0165-0327(81)90044-6.
Among 33 out-patients with endogenous depression, 16 were treated with bromocriptine (10-60 mg/day, mean 34) and 17 with imipramine (75-250 mg/day, mean 143). The total score on the Hamilton Rating Scale decreased during 6-week treatment from 19.9 to 7.8 in the bromocriptine group (P less than 0.001) and from 20.1 to 6.1 in the imipramine group (P less than 0.001). There was no significant difference between the two groups. The main side-effects were for bromocriptine: nausea, dizziness, and headache; for imipramine; dryness of mouth, dizziness, and sweating. This study suggests an antidepressant effect of bromocriptine although, due to the possibility of Type II error, it may not necessarily be equal to that of imipramine.
在33例内源性抑郁症门诊患者中，16例接受溴隐亭治疗（10 - 60毫克/天，平均34毫克），17例接受丙咪嗪治疗（75 - 250毫克/天，平均143毫克）。在为期6周的治疗期间，汉密尔顿评定量表总分在溴隐亭组从19.9降至7.8（P小于0.001），在丙咪嗪组从20.1降至6.1（P小于0.001）。两组之间无显著差异。溴隐亭的主要副作用为：恶心、头晕和头痛；丙咪嗪的主要副作用为：口干、头晕和出汗。本研究提示溴隐亭有抗抑郁作用，尽管由于存在II类错误的可能性，其效果不一定等同于丙咪嗪。
